BIO Board member tells Congress WTO IP waivers hurt innovation
A proposed World Trade Organization (WTO) IP waiver could have scuttled investment in biotech’s new diabetes drug and already impacts the firm’s decisions about […]
BIO Board member tells Congress WTO IP waivers hurt innovation Read More »